Please try another search
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Carole S. Ben-Maimon | 62 | 2020 | CEO, President & Director |
Joseph Truitt | 56 | 2020 | Independent Chairman of the Board |
Jonathan S. Leff | 54 | 2020 | Independent Director |
Giovanni Manfredi | - | 2020 | Member of Scientific Advisory Board |
Mark Payne | - | 2020 | Member of Scientific Advisory Board |
Frank E. Thomas | 53 | 2014 | Independent Director |
Jill Ostrem | - | 2022 | Member of Scientific Advisory Board |
Thomas Edward Hamilton | 55 | 2020 | Independent Director |
Marni Joy Falk | - | 2020 | Member of Scientific Advisory Board |
Jeffrey W. Sherman | 69 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review